Market Cap 149.96B
Revenue (ttm) 62.58B
Net Income (ttm) 7.77B
EPS (ttm) N/A
PE Ratio 8.73
Forward PE 8.94
Profit Margin 12.42%
Debt to Equity Ratio 0.74
Volume 35,355,800
Avg Vol 44,402,004
Day's Range N/A - N/A
Shares Out 5.70B
Stochastic %K 84%
Beta 0.34
Analysts Sell
Price Target $28.60

Company Profile

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States and internationally. It operates in three segments: Biopharma, PC1, and Pfizer Ignite. The company offers internal medicine products, including cardiovascular metabolic diseases products under the Eliquis brand; migraine products under the Nurtec ODT/Vydura and Zavzpret brand; vaccines under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands;...

Industry: Drug Manufacturers - General
Sector: Healthcare
Phone: 212 733 2323
Address:
66 Hudson Boulevard East, New York, United States
GordoHLYK13
GordoHLYK13 Aug. 14 at 2:19 PM
$IGC is entering a historic inflection point—with its first true Phase 2 binary catalyst, advancing regulatory infrastructure, and growing clinical-data capabilities, a successful CALMA readout could dramatically re-rate the company and unlock a whole new valuation tier. 🚀📈 $PFE $ABBV
0 · Reply
chop14
chop14 Aug. 14 at 2:15 PM
$ARTL still nice but still low volume ! $JNJ $PFE $SLDB $LLY
0 · Reply
pineconecameo
pineconecameo Aug. 14 at 2:07 PM
$PFE back to $27 and $NVDA $230 ♻️
0 · Reply
Micheal_Pothead
Micheal_Pothead Aug. 14 at 1:55 PM
$PFE another reminder that max pain today is 26.50 🫩
0 · Reply
Makingmillions192
Makingmillions192 Aug. 14 at 1:55 PM
$LEXX More info on our new partner… PegBio (PegBio Co., Ltd.) is a publicly traded biopharmaceutical company founded in 2008 and based in Hangzhou, China. It focuses on discovering and developing long-acting therapeutic drugs for metabolic and chronic conditions like type-2 diabetes and obesity using specialized PEGylation technology. Key Products and PipelinePB-119 (Visepegenatide): A long-acting GLP-1 receptor agonist designed for once-weekly diabetes management, which gained approval and commercialization in China. Other Candidates: The company develops additional pipeline assets—such as PB-718, PB-1902, PB-722, PB-2301, and PB-2309—targeting obesity, diabetes, and metabolic dysfunction-associated steatohepatitis (MASH). Recent Partnerships: PegBio entered a material transfer agreement with Lexaria Bioscience to evaluate oral delivery applications using DehydraTECH technology for proprietary GLP-1 molecules. $LLY $NVO $PFE $AMGN
0 · Reply
Micheal_Pothead
Micheal_Pothead Aug. 14 at 1:36 PM
$PFE lmfao
0 · Reply
JuggernautRaider
JuggernautRaider Aug. 14 at 1:26 PM
$TNXP eh….. i like $BMY $PFE and $GILD . Tonix is run like 💩 Do your own @Duediligence20 hmm Who has been following me? I need to delete this and get outta here 👍 ☘️ 🫡 🇺🇸 🚘 ⚡️ 🚀
0 · Reply
Micheal_Pothead
Micheal_Pothead Aug. 14 at 1:11 PM
$PFE where we closing today?
2 · Reply
TraderDaKing
TraderDaKing Aug. 14 at 12:00 PM
$ELTP $DJT $GME $PFE $WEN Great News. THIS IS THE MOST IMPORTANT THING WE GOT FROM THE 10Q Date: 8/13/2026 Form: 10-Q - Quarterly Report NOTE 9. COMMITMENTS AND CONTINGENCIES On August 17, 2023, Elite filed a paragraph IV certification with its ANDA to generic OxyContin® and after Elite got acceptance of the ANDA by the FDA on September 19, 2023, Elite sent the patentee and NDA holder a Notice Letter as required under the Hatch-Waxman Act. On November 14, 2023, a patent infringement suit was filed in the District Court of New Jersey by Purdue Pharma. The Parties agreed to a stipulated dismissal of the case and the judge signed the order dismissing the case on June 12, 2026. Elite’s launch of a generic OxyContin® will depend on the approval by the FDA. WILL TRUMP AND RFKJR ON OUR SIDE WE READY FOR THE NEXT LEVEL. ( up-listing ) and merger and or partnership. I'm buying all I can today. This is what I was looking for.
1 · Reply
CharlieeMungerTWITS
CharlieeMungerTWITS Aug. 14 at 11:40 AM
$CELC I call it now - $PFE will acquire celc because there’s no reason to collect 14% on an fda approved drug that will generate $3B. NCCN inclusion ahead of commercial launch is significant. It helps establish REVTORPYK in the treatment pathway before Celcuity even begins the full commercial rollout. * $30,000 per cycle WAC is substantial. That’s roughly a 25% premium to Piqray, according to the Needham note. Management had previously telegraphed premium pricing, so they’re apparently getting it. Before pricing was announced, Leerink had estimated around $29K/month. * 9.0–9.7 months treatment duration is encouraging commercially. At $30K/cycle, duration matters enormously to eventual revenue per patient. * Expanded Access Program before launch means physicians can begin getting experience with REVTORPYK rather than everything waiting for the late-Q3 commercial launch.
1 · Reply
Latest News on PFE
Pfizer Earnings Call Transcript: Q2 2026

Aug 4, 2026, 10:00 AM EDT - 10 days ago

Pfizer Earnings Call Transcript: Q2 2026


Pfizer Earnings release: Q2 2026

Aug 4, 2026, 10:00 AM EDT - 10 days ago

Pfizer Earnings release: Q2 2026


Pfizer Slides: Q2 2026

Aug 4, 2026, 10:00 AM EDT - 10 days ago

Pfizer Slides: Q2 2026


Pfizer Quarterly report: Q2 2026

Aug 4, 2026, 10:00 AM EDT - 10 days ago

Pfizer Quarterly report: Q2 2026


Pfizer Post Loss on Higher Revenue

Aug 4, 2026, 7:24 AM EDT - 10 days ago

Pfizer Post Loss on Higher Revenue

PFE


Options Corner: PFE Downgrade, Stock Slides Near 52-Week Low

Jul 6, 2026, 10:00 AM EDT - 5 weeks ago

Options Corner: PFE Downgrade, Stock Slides Near 52-Week Low

PFE


Pfizer Declares Third-Quarter 2026 Dividend

Jun 24, 2026, 3:52 PM EDT - 7 weeks ago

Pfizer Declares Third-Quarter 2026 Dividend

PFE


Pfizer dismissed from US states' drug price-fixing lawsuit

Jun 24, 2026, 10:51 AM EDT - 7 weeks ago

Pfizer dismissed from US states' drug price-fixing lawsuit

PFE


Pfizer CFO Dave Denton to step down, leave company in August

Jun 18, 2026, 6:52 AM EDT - 2 months ago

Pfizer CFO Dave Denton to step down, leave company in August

PFE


Pfizer Announces Chief Financial Officer Transition

Jun 18, 2026, 6:45 AM EDT - 2 months ago

Pfizer Announces Chief Financial Officer Transition

PFE


US FDA approves Pfizer's bleeding disorder drug for children

Jun 8, 2026, 6:49 AM EDT - 2 months ago

US FDA approves Pfizer's bleeding disorder drug for children

PFE


Pfizer Transcript: Study update

Jun 6, 2026, 11:00 AM EDT - 2 months ago

Pfizer Transcript: Study update


Pfizer Slides: Study update

Jun 6, 2026, 11:00 AM EDT - 2 months ago

Pfizer Slides: Study update


Pfizer Press release: Study update

Jun 6, 2026, 11:00 AM EDT - 2 months ago

Pfizer Press release: Study update


Pfizer Transcript: Jefferies Global Healthcare Conference 2026

Jun 3, 2026, 2:00 PM EDT - 2 months ago

Pfizer Transcript: Jefferies Global Healthcare Conference 2026


GordoHLYK13
GordoHLYK13 Aug. 14 at 2:19 PM
$IGC is entering a historic inflection point—with its first true Phase 2 binary catalyst, advancing regulatory infrastructure, and growing clinical-data capabilities, a successful CALMA readout could dramatically re-rate the company and unlock a whole new valuation tier. 🚀📈 $PFE $ABBV
0 · Reply
chop14
chop14 Aug. 14 at 2:15 PM
$ARTL still nice but still low volume ! $JNJ $PFE $SLDB $LLY
0 · Reply
pineconecameo
pineconecameo Aug. 14 at 2:07 PM
$PFE back to $27 and $NVDA $230 ♻️
0 · Reply
Micheal_Pothead
Micheal_Pothead Aug. 14 at 1:55 PM
$PFE another reminder that max pain today is 26.50 🫩
0 · Reply
Makingmillions192
Makingmillions192 Aug. 14 at 1:55 PM
$LEXX More info on our new partner… PegBio (PegBio Co., Ltd.) is a publicly traded biopharmaceutical company founded in 2008 and based in Hangzhou, China. It focuses on discovering and developing long-acting therapeutic drugs for metabolic and chronic conditions like type-2 diabetes and obesity using specialized PEGylation technology. Key Products and PipelinePB-119 (Visepegenatide): A long-acting GLP-1 receptor agonist designed for once-weekly diabetes management, which gained approval and commercialization in China. Other Candidates: The company develops additional pipeline assets—such as PB-718, PB-1902, PB-722, PB-2301, and PB-2309—targeting obesity, diabetes, and metabolic dysfunction-associated steatohepatitis (MASH). Recent Partnerships: PegBio entered a material transfer agreement with Lexaria Bioscience to evaluate oral delivery applications using DehydraTECH technology for proprietary GLP-1 molecules. $LLY $NVO $PFE $AMGN
0 · Reply
Micheal_Pothead
Micheal_Pothead Aug. 14 at 1:36 PM
$PFE lmfao
0 · Reply
JuggernautRaider
JuggernautRaider Aug. 14 at 1:26 PM
$TNXP eh….. i like $BMY $PFE and $GILD . Tonix is run like 💩 Do your own @Duediligence20 hmm Who has been following me? I need to delete this and get outta here 👍 ☘️ 🫡 🇺🇸 🚘 ⚡️ 🚀
0 · Reply
Micheal_Pothead
Micheal_Pothead Aug. 14 at 1:11 PM
$PFE where we closing today?
2 · Reply
TraderDaKing
TraderDaKing Aug. 14 at 12:00 PM
$ELTP $DJT $GME $PFE $WEN Great News. THIS IS THE MOST IMPORTANT THING WE GOT FROM THE 10Q Date: 8/13/2026 Form: 10-Q - Quarterly Report NOTE 9. COMMITMENTS AND CONTINGENCIES On August 17, 2023, Elite filed a paragraph IV certification with its ANDA to generic OxyContin® and after Elite got acceptance of the ANDA by the FDA on September 19, 2023, Elite sent the patentee and NDA holder a Notice Letter as required under the Hatch-Waxman Act. On November 14, 2023, a patent infringement suit was filed in the District Court of New Jersey by Purdue Pharma. The Parties agreed to a stipulated dismissal of the case and the judge signed the order dismissing the case on June 12, 2026. Elite’s launch of a generic OxyContin® will depend on the approval by the FDA. WILL TRUMP AND RFKJR ON OUR SIDE WE READY FOR THE NEXT LEVEL. ( up-listing ) and merger and or partnership. I'm buying all I can today. This is what I was looking for.
1 · Reply
CharlieeMungerTWITS
CharlieeMungerTWITS Aug. 14 at 11:40 AM
$CELC I call it now - $PFE will acquire celc because there’s no reason to collect 14% on an fda approved drug that will generate $3B. NCCN inclusion ahead of commercial launch is significant. It helps establish REVTORPYK in the treatment pathway before Celcuity even begins the full commercial rollout. * $30,000 per cycle WAC is substantial. That’s roughly a 25% premium to Piqray, according to the Needham note. Management had previously telegraphed premium pricing, so they’re apparently getting it. Before pricing was announced, Leerink had estimated around $29K/month. * 9.0–9.7 months treatment duration is encouraging commercially. At $30K/cycle, duration matters enormously to eventual revenue per patient. * Expanded Access Program before launch means physicians can begin getting experience with REVTORPYK rather than everything waiting for the late-Q3 commercial launch.
1 · Reply
La_Parka3
La_Parka3 Aug. 14 at 10:26 AM
$MRNA $PFE $GSK $SNY An anti vaxxer doing his research:
1 · Reply
notreload_ai
notreload_ai Aug. 14 at 10:09 AM
$VALN shares surge after EMA validates its Lyme disease vaccine candidate developed with $PFE . Phase 3 trial showed over 70% efficacy. https://notreload.xyz/xy/valneva-shares-jump-as-ema-validates-lyme-vaccine-with-pfizer/
0 · Reply
GordoHLYK13
GordoHLYK13 Aug. 14 at 8:10 AM
$IGC $ABBV $PFE $JNJ What are you waiting for ? A diamond in the rough
0 · Reply
focafoca99
focafoca99 Aug. 14 at 5:10 AM
$PFE validated its Lyme disease vaccine candidate's EMA marketing authorization application, marking a key regulatory milestone. https://www.rapidticker.com/news/pfe-pfizer-and-valnevas-lyme-disease-2b16b1
0 · Reply
markbrogan
markbrogan Aug. 14 at 1:06 AM
$PFE i have a feeling insiders know that one or more of their Seagen or Metsera assets are going be great!
0 · Reply
Gemology
Gemology Aug. 13 at 11:44 PM
0 · Reply
Samishere
Samishere Aug. 13 at 11:15 PM
0 · Reply
Gemology
Gemology Aug. 13 at 10:18 PM
$PFE nice&
0 · Reply
Samishere
Samishere Aug. 13 at 7:38 PM
0 · Reply
ZiggyPG
ZiggyPG Aug. 13 at 6:10 PM
$PFE My annual review: Been holding this very dissapointing stock since purchase during COVID. 1 Regret that I did not sell in th high 50's but alas it is a part of the game. Recent positive indicator made me accquire more at the 24-25 price points: 2 Michael Burry bets on Pfizer is now 11% of his scion portfolio. For those who are not familiar with Burry I suggest watching "The Big Short" It may take some time but he is usually on course 3 Recent insider trading including CEO purchase of $1M worth of stock this week. It is a slow burn for sure but I am holding as long as Burry is onboard
1 · Reply
jrh34
jrh34 Aug. 13 at 5:51 PM
$CRDF Perhaps that's already happening - a proxy war with 2 large pharmaceuticals simply using CRDF and NMS as shells to fight over Onvansertib. You'd have $PFE using CRDF and $RHHBY using NMS via the NMS China/Roche Accelerator.
0 · Reply
Makingmillions192
Makingmillions192 Aug. 13 at 4:31 PM
🚀 $LEXX BOOOOM! 🚨 SECOND GLP-1 MTA CONFIRMED! 🚀 This is NOT a drill. Lexaria just dropped a game-changer! Entered into a brand-new Material Transfer Agreement (MTA) with PegBio to process their proprietary GLP-1 molecule via DehydraTECH! 🔥 THE HIGHLIGHTS: 1️⃣ Separate & Independent: This is IN ADDITION to the existing MTA partner. DehydraTECH pipeline is expanding! 2️⃣ Commercial Validation: PegBio has a GLP-1 approved in China (Nov 2025) + Phase 2 assets in US/China across Obesity, Diabetes, & MASH! 3️⃣ Liberi Group BD Delivering: The advisory strategy is executing in REAL TIME. Human trial data drops any day now ⏰ TICK TOCK 💥 🧨 Sub-1.65M float + massive BD validation + Study #7 data dropping next! We are SO BACK! 📈🔥 $VKTX $LLY $NVO $PFE
0 · Reply